Chimiothérapies du cancer de prostate métastatique hormonoréfractaire ou hormonorésistant

25 novembre 2008

Auteurs : M.-O. Timsit, T. Lebret, A. Méjean
Référence : Prog Urol, 2008, 18, S365, suppl. S7
   
 
 

 

 
Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser

   

 

 
 
 

Références

 

Nelson W.G., Saad F., Debruyne F.M.J., et al. New therapeutic targets and treatments for metastatic prostate cancer. In Prostate cancer, 6th International consultation Saad Khouty 2006 ;  6 : 311-344
 
Recommandation 2007 de l’AFU en onco-urologie. Prog Urol 2007;17:1159-230.
 
Heindenreich A., Aus G., Abbou C.C., et al. Guidelines on prostate cancer Guidelines de l’EAU 2008 ;
 
Basch E.M., Somerfield M.R., Beer T.M., Carducci M.A., Higano C.S., Hussain M.H., Scher H.I. American Society of Clinical Oncology American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castrationresistant) prostate cancer J Clin Oncol 2007 ;  25 (33) : 5313-5318 [cross-ref]
 
Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 1996 ;  14 : 1756-1764 [cross-ref]
 
Yagoda A. Cytotoxic agents in prostate cancer: an enigma Semin Urol 1983 ;  1 (4) : 311-321
 
Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 1996 ;  14 (6) : 1756-1764 [cross-ref]
 
Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 2004 ;  351 : 1502-1512 [cross-ref]
 
Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 2004 ;  351 : 1513-1520 [cross-ref]
 
Smaletz O, Scher H.I., Small E.J., et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration J Clin Oncol 2002 ;  20 : 3972-3982 [cross-ref]
 
Halabi S., Small E., Kantoff P., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer J Clin Oncol 2003 ;  21 : 1232-1237 [cross-ref]
 
Shulman M., Benaim E. The natural history of androgen independent prostate cancer J Urol 2004 ;  172 : 141-145 [cross-ref]
 
Smith M., Kabbinavar F., Saad F., et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer J Clin Oncol 2005 ;  13 : 2918-2925 [cross-ref]
 
Smith D.C., Dunn R.L., Strawderman M.S., Pienta K.J. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer J Clin Oncol 1998 ;  16 (5) : 1835-1843 [cross-ref]
 
Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 1999 ;  17 (11) : 3461-3467 [cross-ref]
 
Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 2008 ;  26 (7) : 1148-1159 [cross-ref]
 
Abal M., Andreu J.M., Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action Curr Cancer Drug Targets 2003 ;  3 : 193-203 [cross-ref]
 
Jordan M.A., Wilson L. Microtubules as a target for antidrugs Nat Rev Cancer 2004 ;  4 : 253-265 [cross-ref]
 
Haldar S., Chintapalli J., Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells Cancer Res 1996 ;  56 : 1253-1255
 
Kraus L.A., Samuel S.K., Schmid S.M., Dykes D.J., Waud W.R., Bissery M.C. The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation Invest New Drugs 2003 ;  21 (3) : 259-268 [cross-ref]
 
Leung S.Y., Jackson J., Miyake H., Burt H., Gleave M.E. Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors Prostate 2000 ;  44 (2) : 156-163 [cross-ref]
 
Leung S., Miyake H., Zellweger T., Tolcher A., Gleave M.E. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model Int J Cancer 2001 ;  91 (6) : 846-850 [cross-ref]
 
Tew K.D., Glusker J.P., Hartley-Asp B., Hudes G., Speicher L.A. Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug Pharmacol Ther 1992 ;  56 (3) : 323-339 [cross-ref]
 
Kreis W., Budman D.R., Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines Br J Urol 1997 ;  79 : 196-202 [cross-ref]
 
Chowdhury S., Burbridge S., Harper P.G. Chemotherapy for the treatment of hormone-refractory prostate cancer Int J Clin Pract 2007 Dec ;  61 (12) : 2064-2070 [cross-ref]
 
Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters Nat Rev Cancer 2002 ;  2 : 48-58 [cross-ref]
 
Kamath K., Wilson J., Cabral F., et al. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability J Biol Chem 2005 ;  280 : 12902-12907 [cross-ref]
 
Di Paola R.S., Aisner J Overcoming bcl-2-and p53-mediated resistance in prostate cancer Semin Oncol 1999 ;  26 : 112-116
 
Thalasila A., Poplin E., Shih J., et al. A phase I trial of weekly paclitaxel, 13-cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies Cancer Chemother Pharmacol 2003 ;  52 : 119-124
 
Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 2005 ;  310 : 644-648 [cross-ref]
 
Mackler N.J., Pienta K.J., Dunn R.L., Cooney K.A., Redman B.G., Olson K.B., Fardig J.E., Smith D.C. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone sensitive prostate adenocarcinoma Clin Genitourin Cancer 2007 ;  5 (5) : 318-322 [cross-ref]
 
Zampino M.G., Verri E., Locatelli M., et al. Vinorelbine-based chemotherapy in hormone-refractory prostate cancer Anticancer Res 2006 ;  26 (3B) : 2375-2380
 
Tester W., Ackler J., Tijani L., Leighton J. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma Cancer J 2006 ;  12 (4) : 299-304 [cross-ref]
 
Oh W.K., Manola J., Babcic V., et al. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes Urology 2006 ;  67 : 1235-1240 [inter-ref]
 
Galsky M.D., Small E.J., Oh W.K., et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer J Clin Oncol 2005 ;  23 : 1439-1446 [cross-ref]
 
Rosenberg J.E., Weinberg V.K., Kelly W.K., et al. Activity of secondline chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone Cancer 2007 ;  110 : 556-563 [cross-ref]
 
Rosenber J.E., Galsky M.D., Rohs N.C., et al. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy Cancer 2006 ;  106 : 58-62
 
Beer T.M., Higano C.S., Saleh M, et al. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel Invest New Drugs 2007 ;  25 : 565-570 [cross-ref]
 
Eymard J., Oudard S., Gravis G., et al. Second-line chemotherapy with docetaxel (D) in men treated with docetaxel- based regimen for metastatic hormone-refractory prostate cancer (mHRPC) Asco Prostate Cancer Symposium :  (2007).  (abst. 249).
 
Ross R.W., Beer T.M., Jacobus S., et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel Cancer 2008 ;  112 : 521-526 [cross-ref]
 
Smith M.R., Kaufman D., Oh W., et al. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study Cancer 2000 ;  89 : 1824-1828 [cross-ref]
 
Borden L.S., Clark P.E., Lovato J., et al. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer Cancer 2006 ;  107 : 1093-1100 [cross-ref]
 
Tester W., Ackler J., Tijani L., et al. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone- refractory prostate carcinoma Cancer J 2006 ;  12 : 299-304 [cross-ref]
 
Sternberg C.N., Whelan P., Hetherington P., et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer Oncology 2005 ;  68 : 2-9 [cross-ref]
 
O’Donnell A., Judson I., Dowsett M., et al. Hormonal impact of the 17alpha-hydroxylase/C(17 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer Br J Cancer 2004 ;  90 : 2317-2325
 
Solit D., Ivy Sp., Kopil C., et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer Clin Cancer Res 2007 ;  13 : 1775-1782 [cross-ref]
 
Butler L.M., Agus D.B., Scher H.I., et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo Cancer Res 2000 ;  60 : 5165-5170
 
48 Wedel S.A., Sparatore A., Del Soldato P., et al. New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma J Cell Mod Med 2008 ; [Epub ahead of print].
 
Duque J.L., Loughlin K.R., Adam R.M., Kantoff P.W., Zurakowski D., Freeman M.R. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer Urology 1999 ;  54 : 523-527 [inter-ref]
 
Di Lorenzo G., Figg W.D., Fossa S.D., et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: A Phase 2 Study Eur Urol 2008 ; [Epub ahead of print].
 
Cinar B., De Benedetti A., Freeman M.R. Post transcritpional regulation of the androgen receptor by Mammalian target of rapamycin Cancer Res 2005 ;  65 : 2547-2553 [cross-ref]
 
Whang Y., Wu X., Suzuki H., et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression Proc Natl Acad Sci USA 1998 ;  95 : 5246-5250 [cross-ref]
 
Kaper F., Dornhoefer N., Giaccia A.J. Mutations in the PI3K/ PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions Cancer Res 2006 ;  66 : 1561-1569 [cross-ref]
 
Dahut W.L., Scripture C., Posadas E., et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer Clin Cancer Res 2008 ;  14 : 209-214 [cross-ref]
 
Small E.J., Fontana J., Tannir N., et al. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer BJU Int 2007 ;  100 : 765-769 [cross-ref]
 
Carducci M.A., Saad F., Abrahamsson P.A., et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer Cancer 2007 ;  110 : 1959-1966 [cross-ref]
 
Small E.J., Schelhammer P.F., Higano C.S., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 2006 ;  24 : 3089-3094 [cross-ref]
 
Simons J.W., Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer Urol Oncol 2006 ;  24 : 419-424 [cross-ref]
 
Schwarz G.G. Vitamin D and the epidmiology of prostate cancer Semin Dial 2005 ;  18 : 276-289
 
Yang E.S., Burnstein K.L. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm J Biol Chem 2003 ;  278 : 46862-46868 [cross-ref]
 
Beer T.M., Ryan C.W., Venner P.M., et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators J Clin Oncol 2008 ;  26 : 1900-1901
 
Tolcher A.W., Chi K., Kuhn J., et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer Clin Cancer Res 2005 ;  11 : 3854-3861 [cross-ref]
 
Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy JAMA 1999 ;  281 : 1591-1597 [cross-ref]
 
   
 
 
   

 

© 2008  Elsevier Masson SAS. Tous droits réservés.